Targeting LKB1 in cancer - exposing and exploiting vulnerabilities
M Momcilovic1, D B Shackelford1
1Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Abstract:
The LKB1 tumour suppressor is a serine/threonine kinase that functions as master regulator of cell growth, metabolism, survival and polarity. LKB1 is frequently mutated in human cancers and research spanning the last two decades have begun decoding the cellular pathways deregulated following LKB1 inactivation. This work has led to the identification of vulnerabilities present in LKB1-deficient tumour cells. Pre-clinical studies have now identified therapeutic strategies targeting this subset of tumours that promise to benefit this large patient population harbouring LKB1 mutations. Here, we review the current efforts that are underway to translate pre-clinical discovery of therapeutic strategies targeting LKB1 mutant cancers into clinical practice.
Insights
Liver kinase B1 (LKB1) mutations are common in human cancers. Research is identifying vulnerabilities in LKB1-deficient tumors and translating these findings into clinical treatments for patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The LKB1 (Liver Kinase B1) tumor suppressor is a key regulator of cell growth, metabolism, survival, and polarity.
- LKB1 mutations are frequently observed in various human cancers, leading to deregulation of critical cellular pathways.
Purpose of the Study:
- To review current research efforts focused on translating preclinical discoveries into clinical applications for LKB1-mutant cancers.
- To highlight therapeutic strategies targeting vulnerabilities in LKB1-deficient tumors.
Main Methods:
- Review of preclinical studies and ongoing clinical trials.
- Analysis of cellular pathways affected by LKB1 inactivation.
Main Results:
- Identification of specific vulnerabilities in LKB1-deficient tumor cells.
- Development of promising preclinical therapeutic strategies targeting these vulnerabilities.
Conclusions:
- Significant progress has been made in understanding LKB1's role in cancer.
- Translational research is actively pursuing clinical applications for LKB1-mutant cancer patients, offering potential benefits to a large patient population.
More Related Videos
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
14:34A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31The Intrinsic Apoptotic Pathway
02:53Adaptive Mechanisms in Cancer Cells
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...